Residual DNA testing is becoming an increasingly important part of biopharmaceutical manufacturing in the United States. It helps detect and measure tiny amounts of host cell DNA that may remain in biologics, vaccines, cell therapies, and gene therapies. The goal is simple: ensure that medicines are safe, pure, and meet strict quality requirements.
The USA residual DNA testing sector was valued at USD 154.39 million in 2025 and is expected to reach USD 163.93 million in 2026. By 2035, it is projected to reach around USD 281.22 million, expanding at a 6.18% CAGR from 2026 to 2035.
What Is Driving Growth?
One of the biggest factors is the rapid development of biologics and advanced therapies. Monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies require detailed quality testing throughout production.
As these therapies become more complex, manufacturers need testing methods that can provide accurate results quickly. This is encouraging greater adoption of qPCR, digital PCR, next-generation sequencing, and automated testing platforms.
Outsourcing is another important trend. Smaller biotechnology companies may not have the equipment, expertise, or facilities required for specialized testing. As a result, they increasingly work with contract research and testing organizations that can provide validated analytical services.
Technology Is Changing Testing
Quantitative PCR remained the leading technology in 2025, accounting for 42% of the segment. Its speed, sensitivity, established protocols, and compatibility with routine laboratory workflows make it widely used.
At the same time, next-generation sequencing is gaining attention and is expected to record the fastest growth. Digital PCR is also becoming valuable because it can provide highly sensitive and precise DNA quantification, making it useful for complex biologics and advanced therapies.
Automation is further improving laboratory efficiency by reducing manual work, processing more samples, and lowering the possibility of human error.
Advanced Therapies Create New Opportunities
Cell and gene therapies are expected to be one of the fastest-growing application areas. These treatments require highly sensitive analytical methods because even small amounts of unwanted DNA can affect product quality and regulatory evaluation.
The growing development of personalized medicines, biosimilars, vaccines, and gene-based treatments is therefore creating new opportunities for testing providers and technology companies.
Download a Sample Report: https://www.towardshealthcare.com/download-sample/5972
The Road Ahead
The future of residual DNA testing in the U.S. will likely be shaped by digital PCR, NGS, laboratory automation, high-throughput workflows, and AI-supported data analysis. As biopharmaceutical production continues to expand, reliable testing will remain essential for maintaining product safety and manufacturing consistency.
With the sector projected to reach USD 281.22 million by 2035, residual DNA testing is becoming an increasingly important component of the modern biopharmaceutical quality-control ecosystem.
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium